This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salem, C. Articles by Jones, P. A. Search for Related Content PubMed PubMed Citation Articles by Salem, C. Articles by Jones, P. A.

Progressive Increases in de Novo Methylation of CpG Islands in Bladder Cancer¹

Urologic Research Laboratory [C. S., G. L., Y. C. T., P. A. J.], Department of Preventive Medicine [A-C. F., S. G.], Department of Pathology [P. W. N.], University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California 90089-9181 and ICRF Cancer Medicine Research Unit, St. James’s University Hospital, Leeds, United Kingdom [J. C., M. A. K.]

We conducted a quantitative analysis of the extent of de novo methylation of four CpG islands in human urinary transitional cell carcinomas of different stages and grades to determine how frequently these CpG islands became methylated in transition cell carcinomas during progression. The CpG islands included exon 5 of PAX6, exon 2 of p16, the 5' end of the deleted in bladder cancer gene, and the 5' end of transmembrane protein containing epidermal growth factor and follistatin domains. These sequences were not methylated in normal urothelial tissues; however, 48 of the 54 tumors examined (89%) showed methylation levels in excess of 20% for at least one of the markers. The number of markers concurrently methylated in individual tumors increased with the stage of the tumor, with several of the more aggressive invasive cancers showing hypermethylation of all four markers compared with the less aggressive invasive cancers. However, considerable methylation defects were present in superficial, preinvasive, papillary tumors. These data demonstrate that 89% of bladder cancers have increased methylation of CpG islands relative to their normal counterparts and suggest the occurrence of a hypermethylator phenotype in which multiple independent CpG islands become concurrently methylated in individual tumors in a process associated with tumor progression.

This article has been cited by other articles:

				T. J. Jensen, P. Novak, K. E. Eblin, A. J. Gandolfi, and B. W. Futscher Epigenetic remodeling during arsenical-induced malignant transformation Carcinogenesis, August 1, 2008; 29(8): 1500 - 1508. [Abstract] [Full Text] [PDF]

				C. J. Marsit, E. A. Houseman, A. R. Schned, M. R. Karagas, and K. T. Kelsey Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer Carcinogenesis, August 1, 2007; 28(8): 1745 - 1751. [Abstract] [Full Text] [PDF]

				M. O. Hoque, S. Begum, O. Topaloglu, A. Chatterjee, E. Rosenbaum, W. Van Criekinge, W. H. Westra, M. Schoenberg, M. Zahurak, S. N. Goodman, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst, July 19, 2006; 98(14): 996 - 1004. [Abstract] [Full Text] [PDF]

				C. J. Marsit, M. R. Karagas, A. Andrew, M. Liu, H. Danaee, A. R. Schned, H. H. Nelson, and K. T. Kelsey Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer Cancer Res., August 15, 2005; 65(16): 7081 - 7085. [Abstract] [Full Text] [PDF]

				J. W.F. Catto, A.-R. Azzouzi, I. Rehman, K. M. Feeley, S. S. Cross, N. Amira, G. Fromont, M. Sibony, O. Cussenot, M. Meuth, et al. Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma J. Clin. Oncol., May 1, 2005; 23(13): 2903 - 2910. [Abstract] [Full Text] [PDF]

				M. G. Friedrich, D. J. Weisenberger, J. C. Cheng, S. Chandrasoma, K. D. Siegmund, M. L. Gonzalgo, M. I. Toma, H. Huland, C. Yoo, Y. C. Tsai, et al. Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients Clin. Cancer Res., November 15, 2004; 10(22): 7457 - 7465. [Abstract] [Full Text] [PDF]

				P. S. Yan, H. Shi, F. Rahmatpanah, T. H-C. Hsiau, A. H-A. Hsiau, Y.-W. Leu, J. C. Liu, and T. H.-M. Huang Differential Distribution of DNA Methylation within the RASSF1A CpG Island in Breast Cancer Cancer Res., October 1, 2003; 63(19): 6178 - 6186. [Abstract] [Full Text] [PDF]

				M. Velicescu, D. J. Weisenberger, F. A. Gonzales, Y. C. Tsai, C. T. Nguyen, and P. A. Jones Cell Division Is Required for de Novo Methylation of CpG Islands in Bladder Cancer Cells Cancer Res., April 1, 2002; 62(8): 2378 - 2384. [Abstract] [Full Text] [PDF]

				M. W. Y. Chan, L. W. Chan, N. L. S. Tang, J. H. M. Tong, K. W. Lo, T. L. Lee, H. Y. Cheung, W. S. Wong, P. S. F. Chan, F. M. M. Lai, et al. Hypermethylation of Multiple Genes in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients Clin. Cancer Res., February 1, 2002; 8(2): 464 - 470. [Abstract] [Full Text] [PDF]

				T. Ueki, M. Toyota, H. Skinner, K. M. Walter, C. J. Yeo, J.-P. J. Issa, R. H. Hruban, and M. Goggins Identification and Characterization of Differentially Methylated CpG Islands in Pancreatic Carcinoma Cancer Res., December 1, 2001; 61(23): 8540 - 8546. [Abstract] [Full Text] [PDF]

				R. Maruyama, S. Toyooka, K. O. Toyooka, K. Harada, A. K. Virmani, S. Zochbauer-Muller, A. J. Farinas, F. Vakar-Lopez, J. D. Minna, A. Sagalowsky, et al. Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features Cancer Res., December 1, 2001; 61(24): 8659 - 8663. [Abstract] [Full Text] [PDF]

				M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman A Gene Hypermethylation Profile of Human Cancer Cancer Res., April 1, 2001; 61(8): 3225 - 3229. [Abstract] [Full Text]

				C. A. Eads, R. V. Lord, K. Wickramasinghe, T. I. Long, S. K. Kurumboor, L. Bernstein, J. H. Peters, S. R. DeMeester, T. R. DeMeester, K. A. Skinner, et al. Epigenetic Patterns in the Progression of Esophageal Adenocarcinoma Cancer Res., April 1, 2001; 61(8): 3410 - 3418. [Abstract] [Full Text]

				A. K. Virmani, C. Muller, A. Rathi, S. Zoechbauer-Mueller, M. Mathis, and A. F. Gazdar Aberrant Methylation during Cervical Carcinogenesis Clin. Cancer Res., March 1, 2001; 7(3): 584 - 589. [Abstract] [Full Text]

				G. Liang, K. D. Robertson, C. Talmadge, J. Sumegi, and P. A. Jones The Gene for a Novel Transmembrane Protein Containing Epidermal Growth Factor and Follistatin Domains Is Frequently Hypermethylated in Human Tumor Cells Cancer Res., September 1, 2000; 60(17): 4907 - 4912. [Abstract] [Full Text]